|
|
Article: Can-Fite Completed Patient Enrollment for the Phase II Trial in Dry Eye Syndrome with CF101.
- Article from:
- Business Wire
- Article date:
- January 28, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Company Expects to Release Data On Q2 2009;
The Dry Eye Syndrome Market Cap is Currently Estimated to be US$ 1 Billion
PETACH TIKVA, Israel -- Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 80 patients in its phase II Dry Eye Syndrome trial. Approximately 80 patients were enrolled to this study, randomized into 2 groups treated with 1 mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 6 sites in Israel. The company expects to release study data on Q2 2009.
Dry Eye ...